Tipifarnib

Generic Name: Tipifarnib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₂Cl_₂N_₄O

CAS Number: 192185-72-1

Unique Ingredient Identifier: MAT637500A

Background: Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication: Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: tipifarnib

First Posted Date: 2005-01-10

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 24

Registration Number: NCT00101153

Locations: 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: tipifarnib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2005-01-10

Last Posted Date: 2013-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00101296

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Stage IV Breast Cancer
Recurrent Breast Carcinoma

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Tipifarnib
Other: Laboratory Biomarker Analysis

First Posted Date: 2005-01-07

Last Posted Date: 2015-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00100750

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloblastic Leukemia With Maturation (M2)
de Novo Myelodysplastic Syndromes
Untreated Adult Acute Myeloid Leukemia
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Pure Erythroid Leukemia (M6b)
Childhood Myelodysplastic Syndromes
Adult Acute Eosinophilic Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)

Interventions: Drug: cytarabine
Drug: idarubicin
Drug: tipifarnib

First Posted Date: 2004-11-09

Last Posted Date: 2014-05-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT00096122

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Phase 3

Completed

Conditions: Myelodysplastic Syndrome With Excess Blasts
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With Minimal Differentiation
Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
Adult Erythroleukemia
Adult Pure Erythroid Leukemia
Alkylating Agent-Related Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1

Interventions: Drug: Tipifarnib
Procedure: Clinical Observation

First Posted Date: 2004-10-08

Last Posted Date: 2024-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 144

Registration Number: NCT00093470

Locations: 🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Graham Hospital Association, Canton, Illinois, United States

and more 337 locations

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: tipifarnib

First Posted Date: 2004-10-08

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 296

Registration Number: NCT00093418

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-08-27

Last Posted Date: 2019-11-07

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00004009

Locations: 🇺🇸
University of Iowa College of Medicine, Iowa City, Iowa, United States
🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

R115777 in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-06-18

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00005041

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Neoplasm

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tipifarnib

First Posted Date: 2004-06-11

Last Posted Date: 2018-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00085553

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Nodal Marginal Zone Lymphoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tipifarnib

First Posted Date: 2004-05-19

Last Posted Date: 2020-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 93

Registration Number: NCT00082888

Locations: 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy